Proteins

MK-4101

Cat. No.: HY-100036 CAS No.: 935273-79-3 Molecular Formula: $C_{24}H_{24}F_{5}N_{5}O$ Molecular Weight: 493.47

Target: Smo; Apoptosis; Hedgehog Pathway: Stem Cell/Wnt; Apoptosis Storage: Powder -20°C 3 years

> 4°C 2 years In solvent -80°C 2 years

-20°C 1 year

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: $\geq 50 \text{ mg/mL} (101.32 \text{ mM})$

* "≥" means soluble, but saturation unknown.

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0265 mL	10.1323 mL	20.2647 mL
	5 mM	0.4053 mL	2.0265 mL	4.0529 mL
	10 mM	0.2026 mL	1.0132 mL	2.0265 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	MK-4101 is a Smoothened (SMO) antagonist (IC_{50} of 1.1 μ M for 293 cells) and also a potent inhibitor of the hedgehog pathway (IC_{50} of 1.5 μ M for mouse cells; IC_{50} of 1 μ M for KYSE180 oesophageal cancer cells). MK-4101 has robust antitumor activity that inhibits tumor cell proliferation and induces extensive apoptosis ^[1] .
IC ₅₀ & Target	IC50: 1.1 μ M (293 cells); 1.5 μ M (mouse cells); 1 μ M (KYSE180 oesophageal cancer cells) $^{[1]}$

In Vitro

MK-4101 inhibits Hh signaling both in a reporter gene assay in an engineered mouse cell line with an IC $_{50}$ of 1.5 μ M, and in human KYSE180 oesophageal cancer cells with an IC $_{50}$ of 1 μ M. MK-4101 displaces a fluorescently-labeled cyclopamine derivative from 293 cells expressing recombinant human SMO with an IC $_{50}$ of 1.1 μ M, implying that the compound binds to SMO. MK4101 also inhibits the proliferation of medulloblastoma cells derived from neonatallyirradiated Ptch1^{-/+} mice in vitro with an IC $_{50}$ of 0.3 μ M^[1].

MK-4101 (10 μ M; 60 hours, 72 hours; medulloblastoma or BCC cells) treatment shows cell cycle arrest with a nearly complete disappearance of the S phase subpopulation, a prominent increase of the G1 population and, to a minor extent, of the G2 population^[1].

MK-4101 (10 μ M; medulloblastoma or BCC cells) treatment significantly reduces cyclin D1 protein and accumulation of cyclin B1 protein^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	Medulloblastoma or BCC cells	
Concentration:	10 μΜ	
Incubation Time:	60 hours, 72 hours	
Result:	Showed cell cycle arrest.	

Western Blot Analysis $^{[1]}$

Cell Line:	Medulloblastoma or BCC cells	
Concentration:	10 μΜ	
Incubation Time:		
Result:	Significant reduction of cyclin D1 protein and accumulation of cyclin B1 protein.	

In Vivo

MK-4101 (40-80 mg/kg; oral administration; for 3.5 weeks; CD1 nude female mice) treatment shows tumor growth inhibition (40 and 80 mg/kg) and tumor regression at the highest dose (80 mg/kg). MK-4101 treatment shows a dose-dependent down-regulation of Gli1 mRNA. The maximum effect for tumor inhibition and hedgehog pathway downregulation is achieved at 80 mg/kg $^{[1]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-weeks old CD1 nude female mice with medulloblastoma/BCC ${\sf cells}^{[1]}$	
Dosage:	40 or 80 mg/kg once a day, 80 mg/kg twice a day	
Administration:	Oral administration; for 3.5 weeks	
Result:	Showed tumor growth inhibition (40 and 80 mg/kg) and tumor regression at the highest dose (80 mg/kg).	

REFERENCES

[1]. Filocamo G et al. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma. Mol Cancer Ther. 2016 Jun;15(6):1177-89.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com